ResMed (RMD) and QBE Insurance (QBE) are positioning themselves as potential growth vehicles heading into 2026, though the article presents this as speculative positioning rather than fundamental catalysts. The framing as "next growth investment" suggests retail interest in identifying undervalued or underappreciated equities in the healthcare devices and insurance sectors.
ResMed operates in digital health and cloud-connected medical devices—a sector with secular tailwinds from aging populations and chronic disease management. However, valuation methodology becomes critical; the article's focus on "how to put a value" indicates the market may be repricing these names based on forward multiples rather than near-term earnings surprises. This reflects typical analyst narrative during periods of consolidation.
QBE's inclusion alongside a healthcare stock is noteworthy, suggesting a defensive-growth rotation or a value-hunting narrative spanning uncorrelated sectors. Insurance valuations remain sensitive to interest rate cycles and underwriting discipline—macro variables rather than company-specific drivers.
Sector implication: The dual-sector mention signals fragmented investor interest in pockets of relative value rather than broad sector rotation. Both stocks face structural headwinds (healthcare reimbursement pressure for RMD; reserve adequacy for QBE) that require idiosyncratic thesis development beyond passive momentum.